Rajeev Aurora and Zachary Buchwald
Provided are systems and methods for inhibiting bone loss in a patient by administering a periodic low dose of RANK agonist to generate in vivo FoxP3+ CD8 T-cells (TcREG). TREG prevent the activation of self-reactive T-cells and suppress inflammation by a number of mechanisms, including inhibiting secretion of IL-10. Thus, the ability of TcREG to limit bone resorption and inflammation could be used to treat conditions like osteoporosis and rheumatoid arthritis.
Intellectual Property Status
- U.S. patent pending